RedHill Biopharma to appeal Nasdaq compliance notice
NeutralFinancial Markets

RedHill Biopharma has announced its intention to appeal a compliance notice from Nasdaq, which is significant as it reflects the company's ongoing efforts to meet the exchange's listing requirements. This move is crucial for RedHill as maintaining its listing on Nasdaq is vital for investor confidence and future funding opportunities.
— Curated by the World Pulse Now AI Editorial System